Softbank invested US $5 billion in Roche, a Swiss pharmaceutical giant, and became a major shareholder

People familiar with the matter said that Softbank group has quietly established a US $5 billion stake in Roche, Switzerland, betting on the company’s strategy of using data to develop drugs and become one of Roche’s major shareholders. Softbank believes that the value of Roche’s Genentech is seriously underestimated, and the department focuses on data-based drug discovery and development. At present, Roche is developing a new pill for the new crown virus and is studying a disease treatment for Alzheimer’s disease. In June this year, the United States approved aduhelm, a drug of Biogen company for the treatment of Alzheimer’s disease, which is a positive signal for Roche.